Floatz logo

Genotropin

Prader-Willi Syndrome

Corporacion Parc Tauliprotein_peptidePhase 4 / ApprovedActive
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Prader-Willi Syndrome cohort.

Asset / SponsorPhaseRating
Oxytocin
University Hospital, Toulouse
Phase 2/3BBB
Dccr
Soleno Therapeutics, Inc.
Phase 3BB
Omnitrope
University Hospital, Toulouse
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Liraglutide
Vancouver General Hospital
Phase 4BB

View all 32 →

Same molecule, other indications

Genotropin is also rated in:

isolated congenital growth hormone deficiencyDormant
BBB
Indicative ·
77 / 100
View asset →
lipodystrophyDormant
BB
Indicative ·
71 / 100
View asset →
COVID-19Dormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →